Little did I realize a few grapes could send my blood sugar soaring until I tried the first glucose monitor without a ...

DexCom's revised FY24 sales guidance in the Q2 earnings call led to a $18bn valuation reset. Read why I think DXCM stock is a ...

Ithaka US Growth Strategy highlighted stocks like DexCom, Inc. (NASDAQ:DXCM), in the second quarter 2024 investor letter. DexCom, Inc. (NASDAQ:DXCM) is a medical device company engages in the ...

Objective: Despite several observational studies attempting to investigate the potential association between type 1 diabetes mellitus (T1DM) and the risk of digestive cancers, the results remain ...

Medical device specialist DexCom (NASDAQ: DXCM) is going through a rough patch. The company's shares dropped off a cliff following its second-quarter earnings report. However, zooming out helps ...

DexCom is one of the leaders in an industry with massive growth potential. The company is building a competitive advantage. Despite several risks, it could deliver substantial returns in the long ...

San Diego’s Dexcom began sales this week of Stelo ... A one-off purchase of a single pack with two sensors — which lasts 30 days — costs $99. There’s also a monthly subscription option ...

San Diego’s Dexcom began sales this week of Stelo ... A one-off purchase of a single pack with two sensors — which lasts 30 days — costs $99. There’s also a monthly subscription option, which costs ...

It costs $99 for two sensors (30 days of use) or $89 per month via subscription. Like most CGMs, Stelo provides 24/7 glucose readings to a smartphone app for up to 15 days. The app offers ...